UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma is showing a compelling commercial inflection, with 3Q26 Zusduri revenue of $68.0M beating consensus and rising 35% sequentially, while unique prescribers climbed to 662, repeat prescribers reached about 50% of the total, and activated sites grew to 1,538. The company’s first meaningful quarter of operating income, $8.3M, alongside total revenue of $89.0M, suggests improving operating leverage even as Jelmyto softened to $21.0M on a one-time ~$1.5M CMS true-up and competitive trial pressure. Its outlook is further strengthened by a patent extending coverage into July 2044, FDA acceptance of UGN-103 with a June 14, 2027 PDUFA date, and a pipeline that could extend franchise durability well beyond current exclusivity.

UroGen Pharma is facing a weaker fundamental setup because Jelmyto guidance was cut to about $90M in FY26 from $97M to $101M, signaling a decelerated ramp driven by a one-time ~$1.5M CMS true-up and competitive clinical trial enrollment in LG-UTUC. Zusduri remains too early in its commercial launch to offset that slowdown, while management still provides no formal guidance, leaving the company dependent on a narrow U.S. revenue base from approved products. At the same time, FY26 operating expenses are expected to run toward the upper end of $260M to $270M, with 3Q R&D rising to $26.0M from $14.0M in 3Q25, underscoring margin pressure and execution risk despite a modest 3Q operating income of $8.3M and net loss of $1.5M.